Alexion Pharmaceuticals Inc. (ALXN) announced after the bell Monday that failed to achieve its primary endpoint in its Phase 3 trial of eculizumab, in patients with refractory generalized myasthenia gravis.
from RTT - Before the Bell http://ift.tt/1Y8Joo7
via IFTTT
No comments:
Post a Comment